Summary
Share on X X.com Share on Facebook Facebook Email Email The Federal Bureau of Investigation (FBI) warns the public of noncompliant healthcare providers, to include pharmacies, weight loss clinics, and medical spas, engaging in fraudulent compounding practices by unlawfully misrepresenting compounded weight loss drugs. These misrepresented drugs can pose safety risks and significant health consequences to patients, such as gastrointestinal disorders, nervous system disorders, cardiac disorders, psychiatric disorders, and death. Noncompliant healthcare providers are selling fraudulently compounded drugs claiming to contain semaglutide, the active ingredient in Ozempic and Wegovy, in combination with other ingredients. Some healthcare providers are using compounded mixtures of unknown drugs that do not contain semaglutide, drugs with high levels of impurities, and unsafe or unapproved drugs. Healthcare professionals at medical spas, pharmacies and weight loss centers in multiple states sold fraudulently compounded semaglutide drugs. Testing of the compounded drugs revealed some of the misrepresented compounds did not contain semaglutide and had large percentages of unknown drug impurities.